Steinberg, S3; de Jong, S3; Mattheisen, M3; Costas, J3; Demontis, D3; Jamain, S3; Pietiläinen, O P H3; Lin, K3; Papiol, S3; Huttenlocher, J3; Sigurdsson, E3; Vassos, E3; Giegling, I3; Breuer, R3; Fraser, G3; Walker, N3; Melle, I3; Djurovic, S3; Agartz, I3; Tuulio-Henriksson, A3; Suvisaari, J3; Lönnqvist, J3; Paunio, T3; Olsen, Line3; Hansen, Thomas Folkmann3; Ingason, A3; Pirinen, M3; Strengman, E3; Hougaard, D M3; Orntoft, T3; Didriksen, M3; Hollegaard, M V3; Nordentoft, M4; Abramova, L3; Kaleda, V3; Arrojo, M3; Sanjuán, J3; Arango, C3; Etain, B3; Bellivier, F3; Méary, A3; Schürhoff, F3; Szoke, A3; Ribolsi, M3; Magni, V3; Siracusano, A3; Sperling, S3; Rossner, M3; Christiansen, C3; Kiemeney, L A3; Franke, B3; van den Berg, L H3; Veldink, J3; Curran, S3; Bolton, P3; Poot, M3; Staal, W3; Rehnstrom, K3; Kilpinen, H3; Freitag, C M3; Meyer, J3; Magnusson, P3; Saemundsen, E3; Martsenkovsky, I3; Bikshaieva, I3; Martsenkovska, I3; Vashchenko, O3; Raleva, M3; Paketchieva, K3; Stefanovski, B3; Durmishi, N3; Pejovic Milovancevic, M3; Lecic Tosevski, D3; Silagadze, T3; Naneishvili, N3; Mikeladze, N3; Surguladze, S3; Vincent, J B3; Farmer, A3; Mitchell, P B3; Wright, A3; Schofield, P R3; Fullerton, J M3; Montgomery, G W3; Martin, N G3; Rubino, I A3; van Winkel, R3; Kenis, G3; De Hert, M3; Réthelyi, J M3; Bitter, I3; Terenius, L3; Jönsson, E G3; Bakker, S3; van Os, J3; Jablensky, A3; Leboyer, M3; Bramon, E3; Powell, J3; Murray, R3; Corvin, A3; Gill, M3; Morris, D3; O'Neill, F A3; Kendler, K3; Riley, B3; Craddock, N3; Owen, M J3; O'Donovan, M C3; Thorsteinsdottir, U3; Kong, A3; Ehrenreich, H3; Carracedo, A3; Golimbet, V3; Andreassen, O A3; Børglum, A D3; Mors, O3; Mortensen, P B3; Werge, T5; Ophoff, R A3; Nöthen, M M3; Rietschel, M3; Cichon, S3; Ruggeri, M3; Tosato, S3; Palotie, A3; St Clair, D3; Rujescu, D3; Collier, D A3; Stefansson, H3; Stefansson, K3
1 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 Section of Neurology, Psychiatry and Sensory Sciences, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet3 unknown4 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet5 Section of Neurology, Psychiatry and Sensory Sciences, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet
Epidemiological and genetic data support the notion that schizophrenia and bipolar disorder share genetic risk factors. In our previous genome-wide association study, meta-analysis and follow-up (totaling as many as 18 206 cases and 42 536 controls), we identified four loci showing genome-wide significant association with schizophrenia. Here we consider a mixed schizophrenia and bipolar disorder (psychosis) phenotype (addition of 7469 bipolar disorder cases, 1535 schizophrenia cases, 333 other psychosis cases, 808 unaffected family members and 46 160 controls). Combined analysis reveals a novel variant at 16p11.2 showing genome-wide significant association (rs4583255[T]; odds ratio=1.08; P=6.6 × 10(-11)). The new variant is located within a 593-kb region that substantially increases risk of psychosis when duplicated. In line with the association of the duplication with reduced body mass index (BMI), rs4583255[T] is also associated with lower BMI (P=0.0039 in the public GIANT consortium data set; P=0.00047 in 22 651 additional Icelanders).
Molecular Psychiatry, 2014, Vol 19, Issue 1, p. 108-114
Adult; Aged; Aged, 80 and over; Bipolar Disorder; Chromosome Aberrations; Chromosomes, Human, Pair 16; Europe; Female; Gene Expression Profiling; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; International Cooperation; Male; Middle Aged; Odds Ratio; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Risk Factors; Schizophrenia; Young Adult